Compare KKR & Co Inc (KKR) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Health Care Select Sector SPDR Fund — how do they compare? KKR & Co Inc trades at $95.48 (market cap $87.19B), while Health Care Select Sector SPDR Fund trades at $159.47. The key difference: KKR & Co Inc pays a 0.77% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, KKR & Co Inc nearer its low. Which is the better fit depends on your goals.
| KKR | XLV | |
|---|---|---|
Market Cap | $87.19B | — |
Sector | Financials | — |
52-Week High | $152.16 | $164.48 |
52-Week Low | $83.88 | $129.01 |
Enterprise Value | $12.72B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $97.11, down 3.79% for the day, with a bullish technical signal and strong analyst backing. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic ventures like a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF's North American operations. Financials show robust revenue of $19.21 billion in 2025 and a net income margin of 14.51%, though cash flow from operations has been volatile.
The outlook for KKR is positive, supported by a consensus price target of $120.75 and 89% buy ratings. Key opportunities include growth in renewable energy and private credit, while risks involve high leverage with long-term debt of $49.91 billion and dependence on capital market conditions. Investors should monitor the Q2 2026 earnings release on July 30, 2026, for further direction.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
